A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2011

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 23 Feb 2010 Actual end date changed from Apr 2009 to Nov 2007 as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual patient number (41) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top